In case you missed it, check out our March recap featuring some of the latest in clinical trial news, a new indication for Afinitor, how genetics affect prognosis, and more.
Adapting a Computation Linguistics Model to Surveil for Pancreatic Cancer
An advanced computation linguistics model that can detect pancreatic cysts can help patients prevent pancreatic tumors from forming.
Collaboration Fosters Treatment Advancements for Young Lymphoma Populations
A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.
FDA Assigns BTD and Receives BLA for RP1 Combo in Advanced Melanoma
Vusolimogene oderparepvec in combination with nivolumab has received breakthrough therapy designation from the FDA in advanced melanoma.
Educating Patients and Clinicians on End-of-Life Care and Discussions
Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.
FDA Accepts sNDA for Darolutamide/ADT in Hormone-Sensitive Prostate Cancer
Darolutamide with androgen deprivation therapy has shown promising efficacy and safety results for patients with hormone-sensitive prostate cancer.
Multiple Myeloma Experts Face Off on Sequencing Therapy Options
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.